Navigation Links
Kosan Announces Third Quarter 2007 Financial Results
Date:11/8/2007

g 888.286.8010, access code: 98027185. International callers can dial 617.801.6888, access code: 98027185.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin, and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS- 1022), are being evaluated in Phase 1 clinical trials in hematological cancers and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors.

Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit Kosan's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include, but are not limited to, statements regarding the further development (including the planned commencement of one or more Phase 2 clinical trials and th
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
3. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
4. Kosan Biosciences to Host Research & Development Day on October 31, 2007
5. Kosan to Reacquire Epothilone Program From Roche
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... FL (PRWEB) May 22, 2013 A recent ... of probiotics on athletes to find that those who took ... longer. The results from the study showed that in extreme ... Action, known for their adult acne treatment explains ... and how it may help their skin condition. , ...
(Date:5/22/2013)... Mass. , May 22, 2013  Moderna Therapeutics, ... new treatment modality to enable the in vivo ... John Reynders will join Moderna in ... Reynders is a proven leader in the ... of drug development, from discovery to translation, clinical operations ...
(Date:5/21/2013)... BEACH, Fla. , May 21, 2013 /PRNewswire/ ... FCN ), the global business advisory ... their enterprise value (the "Company"), announced that it ... personnel that were formerly included within the Corporate ... Litigation Consulting segment to form a single integrated ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Custom ... to reporting eLearning solution using Tin Can API ... dashboard tool. CLD is a leading developer of ... medical device companies worldwide. , Tin Can ... that helps learners and trainers more accurately measure ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3
... Singapore investigators to coordinate 700 patient trial of ... of head and neck cancer,MISSISSAUGA, ON, Jan. 5 ... TSX:YM, AIM:YMBA), an oncology company that identifies, develops ... announced that the National Cancer Centre of Singapore ...
... Penn Allegheny,Health System and The Western Pennsylvania Hospital announced ... Jones, MD, FACS,and Roger R. Barrette, MD, formerly of ... Drs. Jones and Barrette will direct the ... for the treatment of burn injuries. West Penn,is ...
... the backdrop of a flagging,economy, bailouts, and bleak ... with a future as bright as New Year,s ... market the Embozene(TM),Color-Advanced Microspheres embolization platform for the ... of blood vessels in many,locations) and arteriovenous malformations ...
Cached Biology Technology:YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE 2YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE 3YM BIOSCIENCES' NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE 4West Penn Allegheny Health System Announces Recruitment of Leading Burn Specialists 2West Penn Allegheny Health System Announces Recruitment of Leading Burn Specialists 3First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform 2First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform 3First U.S. Implants of Newly Approved Embozene(TM) Color-Advanced Microspheres Embolization Platform 4
(Date:5/21/2013)... , Where? Copenhagen, Denmark: Bella Center Congress ... , Why? An annual meeting ... developments, manufacturing and installation, drawing on leading experiences from ... edition from a record of more than 900 abstracts ... plenary and oral presentations, more than 460 visual presentation, ...
(Date:5/21/2013)... May 21, 2013 Royal Philips Electronics (NYSE: ... world,s first portable ultrasound with Philips, industry leading Live ... The CX50 xMATRIX with available Live 3D TEE and ... at the EuroPCR, official meeting for the European ... Since its launch in 2012, Philips CX50 xMATRIX ...
(Date:5/20/2013)... the antibiotic colistin are also commonly resistant to ... to a study in mBio , the ... Microbiology. Cross-resistance to colistin and host antimicrobials LL-37 ... bacterial attack, could mean that patients with life-threatening ... crippled immune response. Colistin is a last-line drug ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... FASEB Journal provide more evidence that if we ... improve. According to MIT scientists, dietary nutrients found in ... eggs increase brain synapses and improve cognitive abilities. ... animals, respond to this kind of treatment by making ...
... State University faculty member who uses computational techniques ... is attracting worldwide attention from other researchers. ... and biomedical engineering at the Florida A&M University-Florida ... computers to determine how substances known as recombinant ...
... alarmed by the dramatic decline of at least 30 percent ... Nepal, once a refuge that boasted among the highest densities ... survey of April 2008 showed a population of between 6-14 ... Government of Nepal made a low-key announcement on July 1 ...
Cached Biology News:FSU researcher using computers to hone cancer-fighting strategies 2Tigers disappear from Himalayan refuge 2
...
... antibody recognizes 30% of IgM-rheumatoid ... It does not cross-react with IgM, ... factor nor with pooled F(Ab)2 fragments. ... ELISA to detect rheumatoid factor. Product ...
...
Salmonella typhimurium Immunogen: Heat inactivated bacterial cells of Salmonella typhimurium B Storage: 4 C...
Biology Products: